非布司他的治疗效果

Gout is a common and complex type of arthritis. People of all ages may suffer from gout. Gout patients often experience sudden joint pain at night. The pain is quite high and feels like a big toe being burned. If not treated in time, the consequences of delay will be that the pain will become stronger and more unbearable. And it can also endanger other normal functions of the body. Also called febuxostat, it is an anti-gout drug. Because febuxostat has a significant inhibitory effect on both oxidized and reduced XOR, febuxostat has a more powerful and long-lasting effect in reducing uric acid. Therefore, febuxostat can be used to treat chronic hyperuricemia in gout. On September 4, 2018, the domestic CFDA officially approved the listing of febuxostat. The domestic febuxostat tablets are also called fibril.  

Febuxostat is a new non-purine xanthine oxidase (XO) selective inhibitor that works by reducing blood urate concentration. It is completely absorbed orally and has a high utilization rate. Food and antacids have no significant effect on its absorption. Unlike allopurinol, its structure is a non-purine analogue, so it is selective in inhibiting xanthine oxidase and has little effect on other enzymes in purine or pyrimidine metabolism. This means that febuxostat is less likely to be affected by other factors and has a stable effect. 

A phase III clinical trial compared the efficacy of febuxostat (80 and 120 mg/d) and allopurinol (300 mg/d) in parallel. A 1-year study of 760 patients showed that compared with the allopurinol group, more patients in the febuxostat group achieved the main trial efficacy indicator - the sUA concentration was measured below 60mg/L in the last 3 months (all subjects were gout patients, and the sUA concentration before the trial were all above 80mg/L); after 52 weeks of treatment, the area of tophi (tophi is gout) was not significantly reduced. Unique aggregates of urate crystals), but this effect was more obvious in the high-dose group early in the trial; in each treatment group, patients with sUA concentration (<60 mg/L) were less likely to have gout attacks, and their tophi area was more significantly reduced; adverse reactions and their incidence rates were similar in each treatment group, including abnormal liver function, diarrhea, headache, joint-related signs and symptoms, and musculoskeletal/connective tissue symptoms.